HLA-C and acute myeloid leukemia: The scFV domain of CAR-T cells binds to antigens expressed on the surface of cancer cells in an MHC-independent manner, therefore, targets for CAR-T therapy are all surface proteins, such as CD33 [138], CD123 [139, 140], NKG2D ligand [141], CD70 [142], CD13-TIM3 [4] for AML patients.